The effects of remimazolam on emergence agitation in patients undergoing nasal surgery: a clinical randomized controlled trial
PeerJ · 19.03.2026 · 14 · e21018
DOI: 10.7717/peerj.21018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PeerJ, online erschienen am 19.03.2026. Verfasst von Xuelei Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, The Second Clinical Medical C…. Hauptthemen laut MEDLINE: Emergence Delirium, Hypnotics and Sedatives, Nasal Surgical Procedures, Postoperative Complications. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Sichuan Provincial Hospital Association.
Abstract (Originalsprache)
Background
Emergence Agitation (EA) is a common postoperative complication, particularly prevalent following nasal surgeries. The occurrence of EA not only elevates the risk of self-inflicted injuries or harm to others but may also lead to a series of severe postoperative complications. This study aims to evaluate the effect of remimazolam on EA in patients undergoing nasal surgery and compare its efficacy with that of conventional anesthetic agents. Materials and methods This randomized controlled trial included 100 patients undergoing elective nasal surgery under general anesthesia from June to September 2024. Patients were randomly assigned (1:1) to the R group (remimazolam) or the C group (propofol). Agitation levels were measured using Riker Sedation-Agitation Scale (SAS), recording each patient’s highest score. The primary outcome was the incidence of EA, with secondary outcomes including hemodynamic parameters, emergence time, and adverse events.
Results
The results indicated that the incidence of EA was significantly lower in the R group compared to the C group (22% vs. 49%; Risk Difference −27% (95% CI [−50% to −0.3%]); Relative Risk 0.45 (95% CI [0.25–0.81]); P = 0.005). Patients in the remimazolam group also demonstrated more stable hemodynamics, with a lower incidence of hypotension (18% vs. 53%, P < 0.001) and significantly reduced occurrence of injection pain (2% vs. 41%, P < 0.001). However, there were no significant differences between the two groups in terms of adverse effects such as bradycardia, postoperative wound bleeding, and postoperative nausea and vomiting.
Conclusions
Remimazolam holds significant clinical application value and potential in surgeries with a high incidence of EA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China.
- Department of Anesthesiology, Meishan City People's Hospital, Meishan, Sichuan, China.
Förderung
- The Sichuan Provincial Hospital Association
Zitieren
APA
Zhou, X., Liu, X., Chen, L., Zhao, L., Mao, W., Zhang, L., Xie, Y., & Li, L. (2026). The effects of remimazolam on emergence agitation in patients undergoing nasal surgery: a clinical randomized controlled trial. PeerJ, 14, e21018. https://doi.org/10.7717/peerj.21018
Vancouver
Zhou X, Liu X, Chen L, Zhao L, Mao W, Zhang L, et al. The effects of remimazolam on emergence agitation in patients undergoing nasal surgery: a clinical randomized controlled trial. PeerJ. 2026;14:e21018. doi:10.7717/peerj.21018
BibTeX
@article{Zhou2026,
author = {Zhou, Xuelei and Liu, Xianchun and Chen, Linlin and Zhao, Li and Mao, Wei and Zhang, Longyi and Xie, Ying and Li, Linji},
title = {The effects of remimazolam on emergence agitation in patients undergoing nasal surgery: a clinical randomized controlled trial},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21018},
doi = {10.7717/peerj.21018}
}
EUVIMED